CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0349 (clinicaltrials.gov NCT No: NCT00429507)
Title:Phase 2 Study of 153 Sm-EDTMP Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients with Bone Only Metastases
Principal Investigator:Naoto Ueno
Treatment Agent:Samarium 153-EDTMP
Study Status:Terminated
Study Description:The goal of this clinical research study is to see if treatment with radiation
from 153 Sm-EDTMP and a stem cell transplant will control breast cancer that
has spread to the bone. The side effects of the study drug will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase II
Treatment Agents:Samarium 153-EDTMP
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Per BMT standard care. In general, 2-3 weeks.
Supported By:N/A
Return Visit:Per BMT standard care. At least 2 times/week for the first two months.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8754
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults